Approximately 40% of diffuse large cell lymphoma are associated with chromosomal translocations that deregulate the expression of the BCL6 gene by juxtaposing heterologous promoters to the BCL-6 coding domain. The BCL6 gene encodes a 95-kDa protein containing six Cterminal zinc-finger motifs and an N-terminal POZ domain, suggesting that it may function as a transcription factor. By using a DNA sequence selected for its ability to bind recombinant BCL-6 in vitro, we show here that BCL-6 is present in DNA-binding complexes in nuclear extracts from various B-cell lines. In transient transfection experiments, BCL6 can repress transcription from promoters linked to its DNA target sequence and this activity is dependent upon specific DNAbinding and the presence of an intact N-terminal half of the protein. We demonstrate that this part of the BCL6 molecule contains an autonomous transrepressor domain and that two noncontiguous regions, including the POZ motif, mediate maximum transrepressive activity. These results indicate that the BCL-6 protein can function as a sequence-specific transcriptional repressor and have implications for the role of BCL6 in normal lymphoid development and lymphomagenesis.
The BCL6 gene was identified by virtue of its involvement in chromosomal translocations affecting band 3q27 in nonHodgkin lymphoma (1) (2) (3) (4) (5) . Subsequent studies have demonstrated that rearrangements of the BCL6 gene can be found in 30-40% of diffuse large cell lymphoma and 6-11% follicular lymphoma (6) (7) (8) . These alterations cause the deregulated expression of the BCL6 gene by a mechanism called promoter substitution, that is the juxtaposition of heterologous promoters, derived from other chromosomes, to the BCL-6 coding domain (9) . Recent evidence also indicates that the 5Ј noncoding region of the BCL6 gene is altered by somatic point mutations that are found, independent of rearrangements, in Ϸ70% diffuse large cell lymphoma and 45% follicular lymphoma (10) . Thus, most cases of diffuse large cell lymphoma and a significant fraction of follicular lymphoma carry structural alterations of the regulatory region of the BCL6 gene, suggesting that deregulated BCL6 expression may be important for lymphomagenesis (11) .
The BCL-6 protein is a 95-kDa nuclear phosphoprotein detectable at low abundance in multiple tissues and expressed at high levels exclusively in mature B cells (12) (13) (14) . Within the B-cell lineage, the expression of the BCL-6 protein is specifically regulated during differentiation since it is only detectable in B cells within germinal centers (GCs) but not in pre-GC cells or in differentiated progenies such as plasma cells (12) (13) (14) . The structure of the BCL-6 protein includes six Krüppel-type C-terminal zinc-finger (ZF) motifs (2, 4, 5) which have been shown to recognize specific DNA sequences in vitro (15, 16) , and a N-terminal POZ (also called ZIN or BTB; refs. [17] [18] [19] motif shared by various ZF molecules including the Drosophila developmental regulators Tramtrack and Broad-complex (20, 21) , the human KUP (22) , ZID (19) , and PLZF (23) proteins as well as by POX viruses (24) and the actin-binding Drosophila oocyte protein Kelch (25) . These structural features and the expression pattern of the BCL-6 protein suggest that it may function as a transcription factor involved in the control of B-cell development.
This study was aimed at elucidating the role of BCL6 in transcriptional regulation. We demonstrate that BCL6 functions as a potent transcriptional repressor of promoters linked to its DNA target sequence and we map this transrepression activity to two noncontiguous N-terminal regions of the protein, one of them including the POZ domain.
MATERIALS AND METHODS
Plasmids. The eukaryotic expression vector pMT2-BCL-6 has been described (12) . To construct the plasmids expressing the Gal4-BCL-6 fusion proteins, various segments of BCL6 cDNA were first obtained by polymerase chain reaction (PCR) using pairs of oligonucleotide primers in which BCL6-specific sequences are linked to a BamHI restriction site and then subcloned into the BamHI restriction site of the Gal4 plasmid (26) . To construct Gal4-BCL-6 fusion protein plasmids with internal BCL6 deletions (constructs J, K, and L; see Fig. 5A ), BCL6 cDNAs were first obtained by PCR using BCL6 primers linked to a 5Ј EcoRI site and a 3Ј SmaI site and then cloned into the Gal4 plasmid to form an intermediate fusion protein construct. A second BCL6 cDNA obtained using primers linked to a 5Ј SmaI site and 3Ј BamHI site was then cloned into the SmaI͞BamHI sites of the intermediate fusion protein construct to create the final construct. All the fusion constructs express Gal4 (amino acids 1-147) fused to variable domains of BCL6 via five residues (PEFPG) encoded by the multiple cloning site of the Gal4 plasmid. Translation termination is provided by three-frame termination codons in the Gal4 plasmid. All PCR-derived sequences as well as subcloning junctions were verified by DNA sequencing. B6BS-TK LUC was constructed by insertion of a single copy of the BCL6 binding site (B6BS: GAAAATTCCTA-GAAAGCATA; B.H.Y. et al., unpublished data) into the BamHI site of TK-LUC. Luciferase reporter constructs (G5-TK-LUC and TK-LUC) were obtained from K. Calame (Columbia University). TK-CAT reporter constructs [G5(ϩ1000)-TK-CAT and G5(-750)-TK-CAT]and SV-CAT reporter constructs [G5-SV-CAT, G5-SVЈ-CAT, and G5(110)-SV-CAT] were obtained from L. Lania (27) and F. Rauscher (28) , respectively (TK, thymidine kinase; CAT, chloramphenicol acetyltransferase; LUC, luciferase; SV, simian virus).
Antisera and Immunoprecipitation. The generation and characterization of polyclonal anti-BCL-6 antisera (N70-6; C73-6) have been described (12) . Polyclonal anti-yeast Gal4 antiserum was obtained from Upstate Biotechnology (Lake Placid, NY).
Cell Lines, Transient Transfection, and Reporter Gene Assays. The Mutu I and Mutu III cell lines were obtained from A.
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Rickinson (29) . Transfections of Mutu III cells (1.5 ϫ 10 7 ) were performed by electroporation using Gene Pulser (Bio-Rad) apparatus. Transfections in NTera-2 cells (from U. Siebenlist, National Institutes of Health), 293T cells (from J. Krolewski, Columbia University), and NIH 3T3 cells were performed by calcium-phosphate precipitation procedure (30) . Assays for LUC and CAT activities were performed as described (30) .
Electrophoretic Mobility Shift Assay (EMSA). Preparation of nuclear extracts, EMSA, and antibody-mediated supershift assays were performed as described (30) except that the EMSA reaction buffer was 20 mM Hepes (pH 7.5), 50 mM KCl, 5 mM MgCl 2 , 10 M ZnCl 2 , 4% Glycerol, and 100 g of BSA per ml. (15, 16) , B6BS contains additional flanking residues that increase affinity and contains unequivocal residues at various previously undefined positions. To determine whether B6BS could serve as a target for naturally synthesized BCL-6 in nuclear extracts, we used it as a probe in an EMSA by using nuclear extracts prepared from B-cell lines expressing (Mutu I) or lacking (Mutu III) BCL6 RNA and protein (12) . Fig. 1 shows that a DNA-binding protein complex was detectable only in nuclear extracts from cells expressing BCL6 (Mutu I), but not in control cells (Mutu III). Cold cognate DNA competition showed that the detected complex bound B6BS specifically; antibody-mediated supershift analysis using antisera against the N-terminus (Fig. 1) or the C-terminus (not shown) of BCL6 showed that this complex contained BCL-6 and that the full-length protein was present in the complex. Analogous EMSA performed on nuclear extracts from a panel of B cells representative of discrete stages of B-cell differentiation indicated complete concordance between formation of BCL-6 containing protein-DNA complexes and protein expression (data not shown). As a further control for specificity, we compared the B6BS-binding complexes in cells (NTera-2; lacking BCL6 expression) transfected with a BCL6 expressing vector or with a control vector (30) . The result (Fig. 1) shows that a DNA-binding complex, specific for B6BS (see cold cognate competition) and containing BCL-6 (see supershift analysis), is also detectable in BCL6 transfected cells, but not in control-transfected cells. The complex detected in NTera-2-transfected cells appeared to be similar in migration and abundance to the one detected in B-cell lines, suggesting either that the BCL-6 protein is the only component of the complex or that, if a cofactor is present, it is expressed in cell types that do not express BCL6. Taken together, these results demonstrate that the B6BS sequence can serve as a DNA target site for in vivo synthesized full-length BCL-6 protein.
RESULTS
BCL6 Represses Transcription from Promoter Linked to Its DNA Target Site. To investigate the role of BCL6 in the regulation of transcription, we analyzed the ability of a BCL6 expression vector to affect the transcription of reporter genes linked to a promoter and the B6BS site in transient transfection assays in Mutu III cells ( Fig. 2A) . Cotransfection of the BCL6 expression vector with a reporter gene (LUC) driven by the constitutively active TK promoter linked downstream to a single-copy B6BS led to a strong (90% using 1 pmol effector plasmid) and dose-dependent repression (Fig. 2B) . The transrepression activity was dependent upon the presence of the FIG. 1. Identification of DNA-binding complexes containing BCL-6 in nuclear extracts from B-cell lines. Nuclear extracts from Mutu I (subclone of lymphoma line, Mutu BL, positive for BCL6 RNA and protein), Mutu III (a subclone of Mutu BL, negative for BCL6 RNA and protein), NTera-2 transfected with a BCL6 expression vector (NTera-2͞BCL-6), or a control vector (NTera-2͞control) were assayed for binding to the B6BS probe by EMSA. Arrows point to BCL-6-containing complexes. Cold cognate oligomer competition was performed using a 10-fold excess of the B6BS probe. Supershift analysis was performed by using an anti-BCL-6 (N70-6) antiserum recognizing the N-terminus of BCL6 or a pre-immune (Pre) serum as a control for specificity. The N-Terminal Half of the BCL-6 Protein Is Capable of Autonomous Transrepression Activity. To conclusively determine whether the N-terminal region of BCL6 contains a transrepression domain and whether this domain was capable of acting autonomously, we tested whether the BCL6 transrepression activity was transferable to an heterologous DNA-binding domain such as the one from the yeast Gal4 transcription factor. We constructed a vector [Gal4-BCL-6(2-517)] expressing a fusion protein in which the non-ZF region (amino acids 2-517) of BCL6 was linked to the Gal4 DNA binding domain (amino acids 1-147) and cotransfected it (293T cells) with a reporter gene construct (G5-TK-LUC) driven by the TK promoter region linked to Gal4 binding sites (G5) (Fig. 3A) . The results (Fig. 3) indicate that the Gal4-BCL-6[2-517] fusion protein is capable of strong (90% repression obtained with 0.1 pmol Gal4-BCL-6 vector) and dose-dependent repression of reporter gene expression. The observed activity is specific since it is dependent upon the presence of the BCL6 domain in the effector vector (see modest activity of Gal4 vector) and the Gal4 DNA binding site in the reporter vector (see modest repression of the TK-LUC reporter gene). Analogous experiments performed using reporter genes driven by minimal promoters (E1B, SV40) lead to some degree of repression (not shown), the specificity of which, however, was difficult to establish due to the low basal activity of these promoters. Taken together, these results indicate that the N-terminal domain of BCL6 (amino acids 2-517) contains a potent autonomous transrepression domain. The Transrepression Activity of BCL6 is Position-, Orientation-, and Distance-Independent. To characterize further the transrepression activity of BCL6, we investigated the effects of varying the distance, 5Ј-3Ј position and orientation between the DNA binding site and the promoter of the reporter gene. Toward this end, the Gal4-BCL-6[2-517] vector was cotransfected into 293T cells with various constructs in which the Gal4 binding site was positioned at variable distance 5Ј [750 bp: G5(-750)-TK CAT; 110 bp: G5(-110)-TK CAT], or 3Ј [G5(ϩ1000)SV-CAT], or at opposite orientations (G5-SVCAT versus G5-SVЈCAT) with respect to the promoters (TK or SV40) driving the CAT reporter gene (Fig. 4) . The results show that the transrepression activity was maintained on all reporter constructs tested. Thus, BCL6-mediated transrepression can act on DNA binding sites independently of their position (3Ј versus 5Ј), orientation and distance from the promoter of the target gene.
Mapping of the BCL6 Transrepression Domain. To determine which region within the N-terminal half (amino acids 2-517) of BCL6 was responsible for the transcriptional repression activity, we constructed various deletion mutants of the BCL6 portion of the Gal4-BCL-6[2-517] vector (Fig. 5A ) and tested their ability to repress the expression of the G5-TK-LUC reporter gene in cotransfection experiments in 293T and in NIH 3T3 cells. In both cell lines, significant loss of activity was associated with mutants lacking a relatively central domain of the BCL6 molecule (amino acids 267-395) (see mutant C versus D), part of the POZ domain (F, G, H, and L), or both (I). In both cell lines, maximal levels of transrepression activity (Ͼ95%), comparable to those obtained with Gal4-BCL-6[2-517], were obtained only in those mutants that retained these two domains, while deletion of variable portions between them was functionally irrelevant (J and K). Accordingly, the presence of only one of the two domains (POZ in E; amino acids 267-395 in F) was insufficient to confer maximal transrepression activity.
The observed reduction in reporter gene activity was not the result of differences in transfection or expression efficiencies among the various effector constructs since immunoprecipitation analysis of transfected cells indicated comparable levels of expression for all Gal4-BCL-6 fusion proteins (representative results in Fig. 5B ). The observed results were not due to differences in subcellular localization or DNA binding among the various proteins since comparable levels of specific DNA binding were observed in nuclear extracts from transfected cells by EMSA using as a probe a synthetic oligonucleotide corresponding to the Gal4 binding site (representative results are shown in Fig. 5C ). Thus, these results indicate that two noncontiguous domains, corresponding to POZ (amino acids 11-121) and to amino acids 267-395, are necessary for maximal transrepression by BCL6.
DISCUSSION
Based on the presence of ZF motifs and a N-terminal POZ domain, previous studies have suggested that the BCL-6 protein may function as a DNA-binding transcription factor (2, 4, 5) . The present study demonstrates that nuclear extracts from B-cell lines contain protein complexes in which BCL-6 binds DNA at it specific target sequence and that BCL6 can repress transcription from promoters linked to the same DNA target site. These results have implications for the function of BCL-6 and other POZ͞zinc finger proteins as well as for the role of BCL6 in normal and neoplastic lymphoid development.
DNA-Binding Complexes Containing BCL-6 in B Cells. Two previous studies have identified DNA consensus sequences capable of binding purified recombinant BCL-6 in vitro (15, 16) . One of this candidate sites was also shown to bind protein complex in nuclear extracts from cells expressing BCL6, but the (1996) presence of BCL-6 within in vivo formed DNA-binding complexes could not be demonstrated (16) . Using a target DNA sequence optimized for in vitro binding to BCL-6 as well as specific immunodetection of BCL-6 in DNA binding assays, we provide direct evidence for the presence of BCL-6 within naturally occurring complexes in various B-cell types (Fig. 1) . This Proc. Natl. Acad. Sci. USA 93 (1996) result validates the B6BS site as the best target for BCL6 in vitro and suggest that this site may represent the target for BCL6 binding in vivo.
Our results also demonstrate that BCL-6 contacts DNA as a full-length protein in in vivo formed protein complexes. This finding is relevant in view of the observation that another POZ͞zinc finger protein, ZID, cannot bind DNA as a fulllength protein and that binding-inhibition is mediated by the POZ domain (19) . Our results exclude the possibility that BCL-6 can only bind DNA in a processed form lacking the POZ domain (19) , but leave open the possibility that other proteins may be present in the complex and necessary for DNA binding by BCL-6. The finding of apparently identical complexes in a variety of cell types either expressing endogenous or exogenous BCL6 (Fig. 1) would suggest that, if a partner protein is present, it is widely expressed in various tissue types.
Transcriptional Repression by BCL6. Our results indicate that the BCL-6 protein can function as a strong transcriptional repressor. Although variable in potency, transrepressor functions have been proposed for other POZ͞ZF proteins including the B isoform of the ␥FBP (33), and the ZF5 (17) and PLZF proteins (23) . Although it remains possible that, similarly to other ZF proteins, the transcriptional activity of POZ͞ZF proteins may be dependent on the cellular environment and may include the ability of transactivate, all POZ͞ZF proteins studied so far have displayed a consistent transrepressive activity in a variety of cell types and on various promoters, suggesting that site-specific transrepression may represent the critical function of these family of nuclear factors. During the preparation of this manuscript, analogous results on the transrepressive activity of BCL6 have also been reported by others (34) .
The mechanism by which transrepression occurs remains to be elucidated. Our results suggest that two noncontiguous domains are necessary for maximal transrepressive activity of BCL6 and a similar conclusion has been recently reached for the highly homologous PLZF protein (J. Licht, personal communication). The first domain virtually coincides with POZ sequences, an evolutionarily conserved motif that has been proposed to mediate protein-protein interactions in large multimeric complexes (35) . The second set of sequences (amino acids 240-395), not previously identified as a distinct functional domain, is characterized by a large number of charged amino acids (35͞155) and proline (21͞155) residues as typically found in regulatory regions of transcriptional modulators. One simple hypothesis to explain the synergistic activity of these two domains is that they may determine the conformation of BCL6 critical for transrepressive function. Alternatively, it is conceivable that the two domains may contribute to transrepression through distinct mechanisms. The POZ domain may be involved in the formation of multimeric protein complexes and their targeting to discrete nuclear substructures (35) , while the structure of the second domain and the ability of BCL6 to act in a distance-and orientation-independent manner are more reminiscent of silencers interfering with the formation of an active transcription complex (36) . The identification of molecules interacting with these two domains should provide insights into their role in BCL6-mediated transrepression.
Implications for the Role of BCL6 in Normal Lymphoid Development and Lymphomagenesis. The BCL-6 protein is expressed in both proliferating and nonproliferating B cells within GCs, but not in pre-GC cells or in differentiated progenies such as plasma cells (12) . This pattern suggests that BCL6 expression may be needed for GC development, while its downregulation may be necessary for differentiation of B cells into plasma cells. Based on these observations, the finding that BCL6 functions as a site-specific transcriptional repressor suggests that BCL6 may regulate the GC phenotype by silencing the genes determining plasma cell differentiation or those preventing the death of B cells within the GC. This implies that the same genes, and thus differentiation and death, may be constitutively repressed in lymphomas in which BCL6 expression is deregulated by promoter substitution or mutation. The results reported in this study provide the experimental framework for the identification of BCL6 target genes.
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